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Abstract
Decoding  the  mechanisms  of  resistance  to  antibiotics  is  essential  in  fighting  a  phenomenon,  which  is 
amplifying everyday due to the uncontrolled excessive and many times unjustified use of anti-microbial substances. At 
present  it  has  become  a  matter  of  public  health,  together  with  the  resistance  of  Mycobacterium  tuberculosis  to 
tuberculostatic or the spreading of the AIDS virus which not only affects the European countries but the entire globe.
This paper presents the genic mutations taking place at the level of bacterial chromosome and inducing the 
resistance to antibiotics.
Introduction
Microbial  resistance  to  antibiotics,  a 
process  that  has  known  a  rapid  uncontrolled 
growth during the last two decades in the entire 
world,  is  widely  accepted  today  as  one  of  the 
major  problems  of  public  health  at  the  world’s 
level [1,2,3]. It manifests itself by the seriousness 
of  infections  or  the  prolonged  clinical 
symptomatology duration, increase in the number 
of hospitalization days, and, last but not least, by 
the resulting costs [4].
The period between the beginning of the 
antibiotics  treatment  (the  1940s)  until  the 
emergence  of  bacteria  expressing  efficient 
mechanisms  of  resistance  is  too  short  (50-60 
years)  to  explain  the  coming  into  being  and 
spreading of the resistance genes only through the 
phenomenon of spontaneous mutation [5,6].
The  solutions  to  the  problems  of  anti-
microbial resistance are a direct consequence of 
understanding the mechanisms at the basis of its 
emergence.  That  is  why  the  genetic  molecular 
mechanisms  resistant  to  antibiotics  must  be 
known in order to successfully fight the resistant 
or  multi-resistant  bacteria  (MDR  – „multidrug 
resistance”).
We frequently refer to bacteria as being 
resistant to antibiotics but we seldom know what 
that  means  [5].  In  the  expert  literature,  the 
definitions are more of the notion of resistance to 
antibiotics.  There  is  resistance  for  a  microbial 
population when the medium concentration of in 
vitro inhibition is bigger than the concentration, 
which can be achieved at the place of the in vivo
infection [7].
Even  the  most  resistant  bacteria  can  be 
inhibited or killed by a high enough concentration 
of  antibiotics. However, not  all the patients can 
tolerate  very  high  bacteriostatic  concentrations 
with a bactericide effect, which would be needed 
in  such  cases.  Bacterial  species  widely  vary  in 
their susceptibility to an antibiotic. For example, 
in  the  United  Kingdom,  most  strains  of  the 
Streptococcus  pneumoniae  are  inhibited  by  a 
minimum  inhibitory concentration  (CMI)  of 
0.01mg/L benzilpenicilline, while the inhibition of 
the growth and multiplication of the Escherichia 
coli  strains a  CMI  of  32-64mg/L  of  the  same 
antibiotic, but this level cannot be reached in the 
human body [5].
From  the  bacteriological  point  of  view, 
Decoster  and  collab.  consider  that  a  strain  is 
resistant when it can develop in the presence of an 
antibiotic  concentration  higher  than  the 
concentration  that  inhibits  most  of  the  strains 
belonging to the same species [8].
More  mechanisms  have  developed  into 
bacteria  gaining  resistance  to  antibiotics.  These 
mechanisms can either chemically transform the 
antibiotic  or  inactivate  it  by  removing  it 
completely  from  the  cell,  or  by  modifying  the 
aimed locus  so  that  the  latter  can  no  longer  be 
recognized by the antibiotic [9,10].
The DNA of the bacteria, no matter what 
their chromosomal, plasmidic (episomal [11]) or 
phagic nature is, may include genes encoding the 
mechanisms  of  resistance  to  drugs,  such  as  the 
inactivating enzymes of the antibiotics, pumps of 
efflux, modification of the antibiotic action target 
etc. [5,9,10].Journal of Medicine and Life  Vol. 2, No.2, April-June 2009 
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Bacterial  resistance  towards  antibiotics 
can  be  natural  (intrinsic,  innate) or  acquired  by 
mutating  the  endogenous  genes  or  by 
incorporating  of  the  exogenous  genes  of 
resistance [5,6,8,10].
1. Natural resistance
Bacteria can have a natural resistance to 
an antibiotic, meaning they can grow and multiply 
in  the  presence  of  maximum  concentrations  of 
antibiotics  tolerated  by  the  body,  their 
development not being influenced by that drug in 
any  way.  For  example,  certain  microorganisms, 
such as the anaerobes, lack a transport system for 
an antibiotic, thus being intrinsically resistant to 
aminoglycoside. Another kind of organisms, i.e. 
mycoplasmas –without a cellular wall – lacks the 
aim for the antibiotic and thus they are naturally 
resistant to the action of the B-lactamic antibiotics 
for the blocking of the cellular wall synthesis, as 
the latter do not possess the enzymes which link 
the  penicillin  (PBP).  In  the  case  of  the  Gram-
negative  bacteria,  the  peptidoglycans  stratum  is 
covered by an exterior membrane which plays the 
part  of  a  hardly  permeable  barrier  especially 
towards  the  penetration  of  antibiotics.  For 
example,  due  to  the  fact  that  the  glycopeptidic
molecules  are  big  (vancomycin – 1448Da  and 
teicoplanin – 1900Da), they cannot penetrate the 
external  membrane  of  the  Gram  negative 
bacteria’s wall, therefore the peptidoglycan is not 
accessible  to  the  action  of  these  antibiotics. 
Similarly,  penicillin  G,  rifampicin,  novobiocin, 
fusidic acid  or  the  macrolide  antibiotics 
(erythromycin)  do  not  penetrate  the  external 
lipopolysaccharidic membrane  of  the  enteric 
Gram negative bacteria (E. coli) [6,10,12].
Certain  pathogenic  organisms,  such  as 
Pseudomonas  aeruginosa,  E.  coli,  Enterobacter 
cloacae,  have  low  permeability  of  the  external 
lipopolysaccharidic  membrane,  thus  constituting 
an obstacle in the diffusion of antibiotics inside 
the bacteria, consequently  such  organisms  show 
natural resistance to a lot of antibiotics [6,9]. For 
example,  the  Ps.  aeruginosa  has  a  natural 
resistance to ampicillin and tetracycline, E. coli to 
vancomicyn etc. [5]. Ps. aeruginosa is naturally 
resistant  to  certain  antibiotics  such  as 
aminopenicillin,  cephalosporin of  the  first  and 
second  generation or kanamycin,  due  to  the 
synthesis  of  β-lactamase associated  with  a  low 
permeability of the cellular wall and a mechanism 
of active constitutive efflux [5,15,16]. It is worth 
noticing that the presence and/or the acquiring of 
a single mechanism of resistance do not always 
confer resistance to an entire class of antibiotics 
and,  consequently,  crossed  resistance  is  not 
always  a  rule.  For  example,  P.  aeruginosa, 
resistant  to  kanamycin stays  sensitive  to 
resembling antibiotics (gentamycin) [6,17].
Natural resistance is genetically supported 
by the bacterial chromosome [6,8]. The bacteria 
that  synthesize  antibiotics  have  to  protect 
themselves from the antibiotic that they produce 
[6,10].  For  example,  Streptomyces  show an 
intrinsic resistance to the antibiotics they produce, 
as  a  mechanism  of  self-protection  from  other 
organisms  tending  to  consume  the  nourishing 
resources in the environment [13]. In Klebsiella 
spp., Enterobacter spp., Serratia spp., Morganella 
spp.,  Providencia  spp.,  or  Ps.  aeruginosa, 
resistance  is  determined  by  the  production  of  a 
chromosomal  beta-lactamase  of  the 
cephalosporinase type  that  inactivates  the  beta-
lactam antibiotics [14,15]. It has been noticed that 
the  genes  that  are  resistant  to  antibiotics  are 
frequently  localized  by  restriction  fragments 
adjoining  those  responsible  of  producing  the 
antibiotic.
Serratia  marcescens naturally  produces 
an  enzyme  codified  by  a  chromosomal  gene 
capable  of  inactivating  the  kanamycin, 
tobramycin, netilmicin  and amikacin, and 
Providencia stuartii produces an enzyme capable 
of inactivating neomycin, gentamicin, tobramycin
and netilmicin [6].
Anaerobic  species  belonging  to  the 
Bacteroides genus and being part  of  the human 
digestive duct microbiota are naturally resistant to
aminopenicillin  and  numerous  cephalosporins 
with  a  wide  spectrum  producing  codified  β-
lactamase  of chromosomal.  The  species 
Staphylococcus  saprophyticus  is  naturally 
resistant to phosphomicine [6].
The  codifying  genes  of  the  resistance 
factors existed before the moment of introducing 
the antibiotics in clinics as they were recognized 
in the bacteria collections created before the use 
of  antibiotics  [5,6].  For  example,  it  was 
discovered  that  a  strain  of  S.  aureus,  isolated 
previously  to  the  discovery  of  antibiotics, 
synthesizes the β-lactamase. It is considered that 
the lysozyme (muramidase) in the nasal secretion 
exercised  a  selective  pressure  favoring  the 
selection of the cells resistant to antibiotics [6,18]. 
The  clavulanic acid  (produced  by  the 
Streptomyces  clavuligerus)  is  a  natural  inhibitor 
of  the  β-lactamase,  conferring resistance  to  β-
lactamic antibiotics.  The  co-production  of 
cephamycin  (a  β-lactamic  antibiotic)  and 
clavulanic acid is constant, meaning that there are 
no known producers of clavulanic acid that do not 
produce cephamycine [6,9,19].
In enterococci (except the E. faecium and
E.  durans) natural  resistance  manifests  in 
lincosamides  and streptogramin A (dalfopristin),Journal of Medicine and Life  Vol. 2, No.2, April-June 2009 
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consequently this type of resistance can be used as 
an orientation test for identification [6,20,21].
Nevertheless, most of the bacteria become 
resistant to antibiotics through one or more genic 
mutations that are further presented in the article.
2. Acquired resistance
The  genic  bacterial  apparatus  is 
represented  by  two  types  of  structures:  the 
nucleoid,  which,  from  the  structural  functional 
point  of  view  corresponds  to  the  chromosome, 
and a second category of structures is represented 
by  the  extrachromosomal  genic  elements 
(plasmids,  transposons,  integrons, sequences  of 
insertion etc.) [6,9,11,22].
According to the two types of structures, 
the  genic  determinants  are  divided  in  two 
categories [6]:
a) essential  genes  (euchromosomal), 
situated in the structure of the chromosome and 
bearing  the  genetic  information  that ensures  the 
development  of  the  essential  functions  for  the 
existence  of  the  cell,  meaning  the  set  of  the 
minimally necessary determinants to  encode  the 
architecture of the cell and to ensure the energetic 
and  biosynthesis  metabolism,  growth,  division 
and regulation of different cell activities, and
b) accessory  genes,  with  plasmidic 
localization or in the structure of the transposable 
genetic  elements  or  phages  bearing  the  genetic 
information that allows the cell to acquire a better 
adaptation  to  new  or  modified  environment 
conditions.
For  example,  after  the  complete 
cartography of the genome E. coli K12, it resulted 
that the latter is made of about 4,400 genes, but 
for  the  growth  of  the  bacteria  in  the  laboratory 
only a few hundred would be necessary [23,24].
Most of the naturally sensitive bacteria to 
antibiotics become resistant due to certain genetic 
chromosomal changes (in 10-20% of the cases) 
or  extrachromosomal  (less  than  80%  of  the 
resistance cases), a process that is called genetic 
resistance [8,22].
The  acquired  antimicrobial  resistance 
emerges  by  the  selection,  consequently  to  the 
exposure  to  antibacterial  drugs  (for  example,  in 
medicine,  agriculture  or  veterinary  practice),  of 
the  species  naturally  resistant  or  due  to  the 
emergence  of  variants  resistant  inside  some 
previously sensitive species [5].
The  exposure  to  antibiotics  is  not  the 
cause  in  itself  for  the  manifestation  of  the 
bacterial  resistance  to  drugs.  The  bacterial 
changes  allowing  the  bacteria  to  resist  to 
antibiotics naturally appear as a consequence  of 
the  mutation  or  as  a  result  of  the  genetic 
combination [5,8,9].
Bacterial  resistance  to  antibiotics  was 
recognized  immediately  that  the  first  antibiotics 
had been introduced in clinics [6,10]. In 1943, in 
certain strains of Stafilococcus aureus, there was 
discovered  the  resistance  to  penicillin  G,  an 
antibiotic that had started to be used since 1941, 
and two decades later, in 1962, two strains of S. 
aureus were made evident for the first time, and 
they  were  resistant  to  methicillin  that  had  been 
introduced in therapy since 1961 [22]. In fact, it 
has  been  ascertained  that  the  emergence  of 
resistance is inevitable after the introduction in the 
market  of  a  new  antibiotic  [10],  and  that  was 
confirmed over the years by the current medical 
practice.  For  example,  in  1962,  ampicillin 
appears,  and  in  1964  the  resistance  of  the 
enterobacteria  to  the  drug  is  emphasized,  or  in 
1980  cephalosporins  started  to be 
commercialized,  followed  in  1981  by  the 
development  of  the  resistance  of  the 
enterobacteria  to  the  previously  mentioned  anti-
microbial  substances  [22].  Consequently  to  the 
studies entered upon it has been noticed that the 
proportion  of  the  bacterial  strains  resistant  to 
antibiotics  varies depending  on  the  country,  the 
species of the organism and the used antibiotic –
victim  to  its  own  therapeutic  success 
[25,26,27,28,29].
Such genes that encode the resistance to 
antibiotics have existed in the natural environment 
of selection of the bacteria even before the use of 
antibiotics  in  therapeutic  practice  [5,6]  (1941  –
penicillin G, discovered in 1929 by Sir Alexander 
Fleming  [10]),  determining  the  capacity  of  a 
species  strains  to  grow  and  multiply  in  the 
presence of maximum concentration of antibiotics 
without any major risks for the human body.
The notion of gene was proposed by WI 
Johannsen (1909) in order to determine the basic 
hereditary  unit,  which  is  localized  in 
chromosomes. The gene is the unity function of 
the  genetic  complex  controlling  a  phenotypical 
character. TH Morgan, in 1911, defines gene as 
being  the  function  unity,  recombination,  and 
mutagenesis,  which  does  not  have  subdivisions 
[30].
The present conception states that gene is 
defined as being the poly-nucleotide segment of 
the  DNA  molecule  holding  the  genetic 
information  necessary  to  the  synthesis  of  a 
polypeptidic  chain  with  specific  structure  and 
function. In other words, the term of gene stays 
associated with the unity of genetic function and 
represents  the  sequence  of  nucleotides  in  the 
DNA, capable to be translated into the sequence 
of amino acids of a protein [30].
An  essential  part  in  the  emergence  and 
development  of  the  bacterial  resistance  to Journal of Medicine and Life  Vol. 2, No.2, April-June 2009 
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antibiotics is played by the genetic variability. It is 
the result of one of the following events: genetic 
mutation, the transfer of genetic material between 
microorganisms  by  transformation,  transduction, 
or conjugation and transposition respectively.
The  genetic  mechanisms  implied  in  the 
acquired resistance can be the mutations affecting 
the genes present on the bacterial chromosome.
Mutations  are  sudden  changes  in  the 
genetic  material  (dowry),  transmissible  and 
definitive (they stay „stable”) in the succession of 
generations, for a character or group of hereditary 
characters,  as  a  reply  to  the  action  of  certain 
modifying factors (endogen or exogenous) [30].
In  prokaryotes,  including  the  bacteria, 
which reproduce by plain mitosis, any mutation is 
transmitted  to  the  descendants  (vertical 
transmission).
As a  definition,  by genetic  mutation  we 
mean  any  disturbance  in  the  sequence  of  the 
genetic code, susceptible to induce the synthesis 
of  a  protein  with  a  flaw  (abnormal  biological 
structure and function).
Genetic mutation is an accidental change 
in the sequence of the polynucleotides of a gene; 
it affects more nucleotides of a sequence or it is 
limited  to  only  one  nucleotide  (in  this  case  we 
deal with a punctiform mutation) of one or both 
catenae of a DNA molecule. Mutation appears as 
an  unpredictable  error  in  the  replication  of  the 
DNA. The different forms of a gene appeared by 
mutation  are  called  allele  and  they  occupy  the 
same genetic locus as the original gene [30].
Reported  to  the  size  of  the  change, 
mutations can be: punctiform or extended.
By  the  modality  of  their  appearance, 
mutations  can  emerge  under  conditions 
considered as normal (natural) – in this case, they 
are  called  spontaneous  mutations,  or  they  can 
emerge  consequently  to  mutagenic  agents  –
induced  or  artificial  mutations.  Subject  to  the 
action of certain physical agents (UV radiations, 
ionizing radiations, visible light, warmth etc.) or 
chemical  ones  (alkyl  agents  analogue  to  the 
nitrogen  bases  – polycyclic  aromatic 
hydrocarbons like bensopiren, nitrogenous acid), 
named  mutagenic  agents,  the  frequency  of  the 
replication  errors  of  the  DNA  grows, 
consequently leading to the growth of the induced 
mutation rate [30].
Mutation has spontaneous character and it 
can appear in any cell (prokaryote or eukaryote) at 
anytime in the cell’s life.
Generally,  the  bacteria  situated  in  the 
stationary stage of the growth line show a single 
circular chromosome of quite variable size [31]. 
In the dividing bacterial cells that contain more 
chromosomes, mutation is produced at the level of 
one  of  the  chromosomes  only,  usually  a  single 
gene being involved, the other homologue genes 
not  being  affected  by  the  mutation,  and  the 
modification of the nucleotide sequence initially 
shows just on one of the 2 complementary catenae 
of the DNA chain.
Regardless of the conditions under which 
they  appear,  spontaneous  or  induced,  mutations 
have an unpredictable character meaning they are 
not specific for a certain genetic locus [30].
The ratio of mutation is the probability of 
the  apparition  of  a  mutation.  It  is  measured  by 
genetic events per cell and per cellular generation. 
It  is  very  reduced,  about  10
-9,  and  for  two 
characters, 10
-18. In other words, the probability of 
the apparition of a mutation for one character is 1 
to each 10
9 cellular divisions. The mutation ratio 
grows as subject to the action of the mutagenic 
agents.  In  addition,  it  grows  considerably  after 
mutations  of  genes  specifying  the  enzymes 
implied  in  the  replication  and  repairing  of  the 
DNA [30].
Under those circumstances, certain genes 
of  resistance  have  appeared  by  accidental 
mutations that offered a selective advantage to the 
carrying cells [10].
The frequency of mutation is defined as 
being  the  proportion  of  a  certain  mutant  in  a 
cellular population. With bacteria, mutations have 
a frequency of 10
-5-10
-9, without being determined 
by the environment, which only plays a part in the 
selection of the mutants. Thus, the frequency can 
grow as a consequence of the selection [30]:
- relative  selection  is  produced  when 
the mutant has a time of generation shorter than 
that of the parental population;
- absolute selection is achieved by an 
environment factor favorable to the development 
of  a  mutant,  yet  unfavorable  to  the  parental 
population. For example, subject to the action of a 
certain  antibiotic,  the  resistant  adequate  favored 
mutants  multiply  and  generate  a  resistant  clone 
while  the  parental  sensible  population  is 
eliminated.
Accordingly,  the  frequency  of  the 
spontaneous  mutation  for  the  resistance  to 
antibiotics is of approximately 10
-8-10
-9 meaning 
that in an infection treated with antibiotics, one at 
each 10
8-10
9 bacteria will develop resistance by 
the process of mutation. In the strains of E. coli it 
has  been  estimated  that  the  resistance  to 
streptomycin  is  acquired  at  a  rate  of 
approximately  10
-9,  when  those  are  exposed  to 
high concentrations of streptomycin [10].
Punctiform  mutations  (micro  evolving 
genetic  modifications)  in  the  structure  of  the 
chromosomal genes can modify the sensibility of Journal of Medicine and Life  Vol. 2, No.2, April-June 2009 
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organisms to antibiotics by structural modification 
of the target. For example, some microorganisms 
modify their β-lactamase as a consequence  of  a 
punctiform  mutation  and  thus  the  scope  of  the 
enzyme extends. Similarly, the mutational change 
of  just  one  amino  acid  in  a  protein  of  the 
ribosomal  subunit 30S determines the resistance 
of  the  cell  to  streptomycin  [6].  It  is  about  a 
mutation in the structure of a codifying gene for 
the small ribosomal unity 30S. Streptomycin does 
not  have  any  relation  with  this  subunit.  If  the 
latter  stays  functional,  a  form of  resistance  has 
been obtained [32].
There  are five  mechanisms of  the  genic 
mutation:  substitution,  deletion,  addition, 
inversion and duplication.
(1) Substitution  – replacement  of  a 
nitrogenic  base  (so  called  nucleotide base)  with 
another – in its turn it can be [30]:
a) Substitution  by  transversing  emerges 
when a purine base (adenine - A -, or guanine - G) 
of a catena is replaced by a pyrimidine (thymine -
T -or cytosine - C), or a pyrimidine one with a 
purine one [33]. This mutation not only affects the 
codon (the  base  triplet  in  the  polynucleotide) 
where the transversing has been produced.
b)  Substitution  of  a  nitrogenic  base 
(purine  base:  A,  G,  or  pyrimidine:  T,  C)  by 
analogue  compounds  of  it  (5  bromouracil or 
fluorouracil) which leads to the alteration of the 
complementary  nucleotide  couple.  The  result  is 
the  emergence  of  a  protein  with  a  punctiform 
structure flaw, different from the old one by the 
respective  new  amino  acid  introduced  in  its 
structure.
c)  Substitution  by  transition,  when  a 
purine  base  of  a  catena  is  replaced  by  another 
purinic base (i.e. A → G) or a pyrimidinic base is 
replaced  by  another  pyrimidinic  base  (T  →  C) 
[33],  changing  the  complementarity  of  the 
nucleotides.
(2) Deletion  (suppression)  of  a  base  in 
the  structure  of  a  gene  affects  all  the  codons 
(triplets)  following  the  point  of  nucleotide 
suppression.
As a direct result of the elimination of a 
nucleotide,  a  protein  with  a  longer  or  shorter 
sequence of amino acids. Thus, if this mechanism 
(deletion) transforms a triplet with „meaning” into 
a  nonsense  triplet  (terminator  codon)  then  the 
sequence  of  amino  acids  will  be  much  shorter 
than  normal.  Or  vice  versa,  if  the  terminator 
triplet (nonsense) is transformed into a triplet that 
codifies an amino acid, then the sequence will be 
much longer than normal [30].
(3) Addition  (insertion)  of  a 
supplementary  nucleotide  in  the  structure  of  a 
gene affects all the codons following the insertion 
point.
(3.1)  Deletion  followed  by  insertion 
affects those codons situated between the deletion 
point  and  the  insertion  point.  The  codons 
following  the  insertion  point  will  have  normal 
„structure”.
(4)The  inversion  of  a  codon  of  a  gene 
structure has a punctiform effect. For example, the 
CCA codon, which codifies proline, by inverting 
the order of the ACC bases will codify histidine. 
The  inversion  of  a  nucleotide  with  another 
nucleotide, thus  modifying  a  codon,  has  similar 
consequences with those of substitution.
(5)Mutation  by  duplication  – deficiency 
leads to the formation of new proteins that can be 
different from the old ones: either the two genes 
associate in order to codify a single protein, the 
sequence  of  which  will  be  a  duplication  of  the 
original  protein,  or  the  two  genes  (created  by 
duplication) will function at the same time so that 
the production of proteins can be modified.
The  vulnerability  of  the  DNA  molecule 
towards chemical factors (alkyl agents, nitrosating
agents,  structural  analogues)  and  physical  (UV 
radiations) creates the premises for the emergence 
of  DNA  „injuries”,  which  generally  consist  of 
[34]:
- purine degradation;
- breaking  of  the  phosphodiesteric 
links;
- cross-linking  of  the  bases  to  the 
opposite catenae;
- change of the tautomeric conditions 
which  leads  to  the  possibility  of  an  erroneous 
coupling  of  bases,  either  in  the  course  of 
replication or by substituting a base belonging to 
DNA by a structural analogue; that is how, due to 
the  fact  that  5  bromouracil  (an  analogue  of 
thymine)  prefers  the  enolic  form  instead  of  the 
cetonic one, adopted by the thymine that couples 
with  the  guanine  not  with  the  adenine,  which 
leads to the replacement of the pair A=T by G≡C 
(transition);
- spontaneous deamination or subject 
to the action of the nitrogenic acid, followed by 
the  formation  of  compounds  that  either  do  not 
couple  with  the  nitrogen  bases  or  they  are 
predisposed  to  erroneous  coupling.  Thus,  by 
deamination, the adenine  leads  to hypoxanthine, 
guanine  to  xanthine,  and  cytosine to  uracil, 
products that are not bases belonging to the DNA 
and they will be recognized and removed by the 
reparation enzymes;Journal of Medicine and Life  Vol. 2, No.2, April-June 2009 
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- dimerization of  thymine,  followed 
by cyclobutanic actions within the same catena;
- insertion  of  one  or  more 
supplementary bases. For example, when cellular 
cultures  are  treated  with  acridine, the  latter 
interferes between two bases of a chain. During 
replication, on the complementary catena, to the 
acridine, a supplementary  base inserts itself and 
links covalently. At a future replication there will 
be a supplementary pair of bases;
- deletion of one or more bases. The 
phenomenon  means  hydrolyzing  a  base  of  the 
chain,  which  is  possible  when  the  pH  and 
temperature vary, or by the action of agents that 
modify a base in such a manner as to make it stop 
being  complementary  to  any  other  base.  By 
replication, the „void” appears on both catenae.
These injuries of the DNA molecules can 
be  corrected  by  two  repairing  mechanisms  that 
detect the injury and repair the injured catena: one 
repairing  constitutive  system  by  excision  –
resynthesis,  and  a  second  one,  the  inducible 
system  of  repairing  – the  SOS  system  –
represented by  a  series  of  factors  of  protein 
nature;  their  fidelity  in  replication  is  just 
approximate,  hence  its  name  of  „reparatory 
system subject to errors”. It is important to notice 
the  fact  that  each  time  a  catena  is  injured,  the 
other will not only serve to keeping the genetic 
information but to repairing the injured catena as 
well [11,34].
The  injuries  escaping  the  repairing 
systems become mutations [34]. The errors of the 
replicative synthesis of the DNA and the inability 
of  the  systems  to  repair  the  DNA  lead  to  a 
frequency  of  spontaneous  mutation  of  a  pair  of 
bases/10
7–10
10 cells, meaning that for each 10
7–
10
10 cells,  only  one  base  suffers  modification. 
Anyway,  the  rate  of  spontaneous  mutation 
generating  resistance  is  lower,  as  for  the 
emergence  of  primary  resistance  multiple 
mutations  are  needed.  That  is  why  it  has  been 
considered  that  the  emergence  of  the  strains 
resistant  to  antibiotics  by  mutational  processes, 
during therapy, is not probable [6].
The expert literature describes numerous 
cases of bacterial resistance to antibiotics, usually 
as a consequence of the apparition of one or more 
spontaneous mutations.
Thus,  some  bacteria  including 
Mycobacterium  tuberculosis  or  Staphylococcus 
aureus  resistant  to  meticilline,  can  acquire 
resistance to rifampicin by a punctiform mutation 
of  the  β-subunit  of  the  RNA  polymerase
depending  on  the  DNA, a  mutation codified by 
the rpoB, which leads to the loss of specificity for 
the  molecule  of  rifampicin. [35,36,37,38]. 
Consequently,  the  RNA  polymerase will  no 
longer show affinity to rifampicin and it will no 
longer be affected by the inhibiting effect of the 
antibiotic.  The  mutations  induced  by  the 
rifampicin are produced in the gene codifying the 
synthesis of the bacterial RNA polymerase; these 
events usually appear in the 3 short regions highly 
preserved  of  the  subunity  β forming  the  area 
known as „the determined region of resistance to 
rifampicin”, comprised between the remains 505 –
534 (in E. coli), at a distance from the active locus 
of  the enzyme. In mycobacterium, over  90% of 
the mutations are due to the modification of one 
nucleotide  of  the  codifying  gene  of  the  β-
subunity.  For  Mycobacterium  tuberculosis,  the 
mutations conferring resistance to rifampicin are 
most frequently found in the codons 531, 526, and 
516 – in descending order of the frequency [39] –
while  in  Staphylococcus  aureus  the  mostly 
identified mutation is in codon 481 [40].
The genetic analysis established that the 
spontaneous  resistance  to  fluoroquinolone  (such 
as ciprofloxacin or norfloxacin) can be the result 
of a punctiform mutation in each of the two genes 
gyrA  and gyrB  that  codify the  two  protein 
subunities of an enzyme, DNA gyrase, fact that 
leads to enough conformational modifications of 
the gyrase, so that the affinity for fluoroquinolone
is  diminished  or  absent  [41,42].  In  a  study 
performed  in  China  in  2007,  Li-Fen  Hu  et  al. 
underlined  the  fact  that  that  the  most  common 
mutation met in 20 isolated bacteria of Shigella 
resistant to fluoroquinolone (47.62% of the cases) 
were in codon 83 of the gyrA (transitions TCG → 
ATC  and  TCG  →  TTG),  resulted  from  the 
replacement  of  the  serine  by  isoleucines  and 
leucine  [43].  In  fact,  the  same  conclusion  was 
previously reported by Dutta et al. in 2005 [44].
Resistance  to  streptomycin  may  appear 
due to the mutations at the level of the genes that 
codify 16S rRNA, thus reducing the affinity of the 
antibiotic for the molecule 16S [45].
The  loss  of  activity  of  the  enzyme 
NADPH  nitroreductase  - that  activates,  at 
intracellular level, the metronidazole in order to 
have antimicrobian effect – can be the result of a 
nonsense deletion or a mutation in the rdxA gene 
[46,47].  Moreover,  the  activity  of  the  NADPH 
nitroreductase could be dramatically reduced  by a 
single spontaneous  mutation (the change  of  one 
amino  acid)  occurred  in  the  strains  of  the 
Helicobacter pylori sensible to metronidazole, a 
fact  that  reduces  its  capacity  to  activate  the 
substance  belonging  to  the  category  of 
nitroimidazoles. All of these mutations have as a 
result the loss of the enzymatic activity necessary 
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consequently  the  bacteria  become  resistant  to 
metronidazole [48,49].
Although  mutation  is  a  rare  event,  the 
quite growing rapid rate of the bacteria and the 
absolute  number of  cells that it  reaches favours 
the quite rapid expression of resistance in a cell 
population.  As  a  consequence  of  the  mutation 
spontaneously  produced  in  the  bacterial 
chromosome,  once the  genes  of  resistance  have 
been stabilized, they can be directly transferred to 
all the descendant cells by replicating the DNA, 
process  known  as  the  transfer  of  genes  on  the 
vertical or the vertical evolution [6,10].
During  the  stress  to  antibiotics,  the 
saprobiontic  bacteria and  the pathogenic  ones, 
plainly  increase  their  rate  of  mutation,  meaning 
they  become  hypermutant.  They  express  and 
duplicate  the  information  of  survival,  also  the 
genes  resistant  to  drugs,  situated on  plasmids, 
transposons and integrons [6]. For example, when 
they  are  under  the  stress  of  antibiotics,  some 
bacteria exchange the genes having a role in the 
synthesis of some proteinic products, which can 
increase the rate of mutation inside the bacteria, 
10,000 times faster than the rate of mutation that 
normally appears in the binary cell division. That 
leads  to  a  kind  of  hyper-evolution  when  the 
mutation acts as a self-defense mechanism for the 
bacteria,  by  growing  the  risk  of  obtaining  an 
antibiotic resistant mutant [9].
It  is  worth  mentioning  the  fact  that  the 
bacteria  have  a  great  capacity  to  preserve  their 
genetic  material  conferring  them  a  selective-
evolutional  advantage  and  preserves  the 
advantageous mutations even in  the presence  of 
the  action  of the  DNA  repairing  mechanisms, 
which tend to correct them [6].
Numerous  cases  of  resistance  of  the 
pathogen  bacterial  to  macrolides  (erythromycin, 
azithromycin,  clarithromycin,  dirithromycin,
troleandomycin etc. [50]) could be caused by the 
mutational alteration of the specific nucleotides of 
the sequence ribosomal RNA (rRNA) 23S of the 
big ribosomal unity 50S [6]. The adenine 2058 or 
the adenine  adjacent to the linking locus of  the 
peptidil-transferase (A2057  or  A2059)  is 
exchanged  with  another  nucleotide  by  mutation 
and  it  confers  a  high  degree  of  resistance  to 
certain macrolide. A lower level of resistance is 
produced  by  the  mutations  in  positions  2057, 
2452,  2611,  situated  outside  the  centre  of 
interaction  of  the  molecule  rRNA  with  the 
macrolide. Mutations perturb the structure of the 
locus of  linking the antibiotic to the RNA 23S, 
hence the decrease of the macrolides’capacity to 
interact  with  the  ribosomes  and  to  inhibit  their 
activity  [6].  The  mechanism  of  this  type  of 
mutational  resistance  has  been  studied  in 
Helicobacter  pylori. The  infectious  agent 
colonizes the stomach in about 30% of the adult 
individuals.  Most  of  the  infections  are 
asymptomatic,  but  the  H.  pylori is  the  main 
aetiologic  agent  of  most  cases  of  gastric  or 
duodenal  ulcers  and  it  is  associated  with  the 
development of certain types of gastric neoplasia. 
The  treatment  of  election  for  the  manifest 
infections is a combination of drugs including a 
derivative  of  erythromycin – clarithromycin and 
an  inhibitor  of  the  of  the  proton  pump  –
omeprazole [50]. The resistance to clarithromycin
may appear during therapy [51] and it has been 
attributed to the mutations in positions A2058 or 
A2059 of the rRNA 23S. In H. pylori there were 
not  identified  any  genes  of  methylation  of  the 
rRNA or systems of efflux of the macrolide. The 
mechanisms of resistance seem to be limited by 
the  emergence  of  mutations  rRNA  23S  [52]. 
Considering the very stable sequence of the rRNA 
in different species of bacteria, it is presumable 
that the identical mutations will produce the same 
phenotype in different bacterial species [6].
The rRNA mutations have been rendered 
evident by the techniques based on PCR [53,54]. 
The area of the codifying gene for the sequence 
adjacent to  the nucleotide A2058, present in H. 
pylori, was amplified and analyzed by the method 
of digestion with enzymes of restriction followed 
by hybridization with oligonucleotide probes with 
specific  sequence  and  visualization  by  self-
radiography  or  by  nonradioactive  techniques. 
Thus  the  loci  of  the  ARNr  mutation  have  been 
identified, which confer resistance to the pathogen 
bacteria in macrolide [6,53]:
- The  emergence  of  mutations  in 
position  A2057  is  limited  to  a  group  of 
propionibacteria resistant to erythromycin and to a 
strain doubly mutant of H. pylori, with a mutation 
at the position 2032, supplementary in comparison 
with substitution 2057.
- Adenosine  2058  is  the  essential 
nucleotide  for  the  interaction  of  the  macrolide 
with the ribosome. Mutation 2058 to G was the 
first  identified  mutation  of  the  ARNr  which 
confers resistance to erythromycin.
- Mutations A2059 to C or G were 
identified in Mycobacterium, Propionibacterium, 
H. pylori and Streptococcus pneumoniae. The in 
vitro experiments showed that the mutants A2059 
in  H.  pylori have  lower  levels  of  resistance  to 
clarithromycin  in  comparison  with  the  mutants 
A2058.Journal of Medicine and Life  Vol. 2, No.2, April-June 2009 
121
© 2009, Carol Davila University Foundation
References
1. World  Health  Organization 
(WHO),  Drug-resistant 
Salmonella, Fact sheet No. 139, 
revised April 2005.
2. National Association of County 
and  City  Health  Officials 
(NACCHO),  Statement  of 
Policy. Enhancing The Capacity 
Of  Local  Health  Departments 
To  Monitor,  Prevent,  And 
Control  Emerging  Multi-Drug 
Resistant  Organisms,  NW, 
Washington  DC,  November  4, 
2007.
3. World Health  Organization 
(WHO),  Anti-tuberculosis  drug 
resistance in the world, Fourth 
Global  Report,  The 
WHO/IUATLD  Global  Project 
on  Anti-tuberculosis  Drug 
Resistance  Surveillance  2002-
2007,  WHO  Press,  Geneva, 
2008.
4. Nicoară E., Crişan A., Bota K., 
Stănescu  D.,  Cerbu  M., 
Găgeanu  R.,  Buzoianu  M., 
Bleşcun  A.,  Rezistenţa  la 
antibiotice  a  tulpinilor  de 
Salmonella izolate în Clinica de 
Boli  Infecţioase,  Revista 
Infecţio.ro, nr. 3, XII 2005.
5. Hawkey P.M., The origins  and 
molecular  basis  of  antibiotic 
resistance,  BMJ 1998;  317: 
657-660.
6.   Mihăescu  G.,  Chifiriuc  M.C., 
Duţu  L.M., Antibiotice  şi 
substanţe  chimioterapeutice 
antimicrobiene,  Editura 
Academiei  Române,  Bucureşti, 
2007.
7.   Schäfller  A.,  Altekrüger  J., 
Microbiologie  medicală  şi 
imunologie,  Editura  All, 
Bucureşti, 1994; p. 101.
8. Decoster A., Lemahieu J.-C.,
Dehecq E., Duhamel M., Cours
de Bactériologie en ligne.
Resistance  aux  antibiotique, 
Faculté  Libre  de  Médecine,
Université  Catholique  de  Lille,
2008,
http://anne.decoster.free.fr/binde
x.html
9.    Kaiser  G.E., BIOL  230 
Microbiology  Lecture  E-Text, 
The  Community  College  of 
Baltimore  County,  Baltimore, 
Maryland,  2007, 
student.ccbcmd.edu/courses/bio
141/lecguide/unit2/control/resist
.html
10.  Todar  K.,  Bacterial  Resistance 
to  Antibiotics,  Todar's  Online 
Textbook  of  Bacteriology, 
University  of Wisconsin,  2008, 
http://www.textbookofbacteriol
ogy.net/
11. Isvoranu M., Pavel D.A., Negru 
A., Genetica umană, vol. I. Curs 
universitar,  Editura  Icar, 
Bucureşti, 2007, p. 57.
12. Dorobăţ  O.M.,  Bacteriologie 
Medicală,  Editura  Printech, 
Bucureşti, 1999.
13.  Challis  G.L.,  Hopwood  D.A., 
Synergy  and  contingency  as 
driving forces for the evolution 
of  multiple  secondary 
metabolite  production  by 
Streptomyces  species, 
Proceedings  of  the  National 
Academy  of  Sciences  of  the 
United States of America 2003; 
100(2): 14555-14561.
14.  Bush K., Jacoby G.A., Medeiros 
A.A, A functional classification 
scheme for β-lactamases and its 
correlation  with  molecular 
structure.  Antimicrob. Agents 
Chemother.,  1995;  39:  1211-
1233.
15. Livermore  D.M.,  Multiple 
mechanisms  of  antimicrobial 
resistance  in  Pseudomonas 
aeruginosa:  our  worst 
nightmare?,  Clin.  Infect.  Dis., 
2002 Mar 1; 34(5): 634-40.
16. Wikipedia,  the  free 
encyclopedia 2008, 
http://en.wikipedia.org/wiki/Pse
udomonas_aeruginosa
17. Todar  K.,  Pseudomonas 
aeruginosa (2008),  Todar's 
Online  Textbook  of 
Bacteriology,  University  of 
Wisconsin, 
http://www.textbookofbacteriol
ogy.net/pseudomonas.html
18. Madigan  M.T.,  Martinko  J.M., 
Parker  J.,  Brock  Biology  of 
Microorganisms,  Tenth  Ed., 
Pearson  Prentice  Hall  Intern. 
Inc., Upper Asddle River, New 
Jersey,  2003;  p:  727-804,  846-
875, 965-994.
19. Livermore  D.M.,  Hope  R., 
Mushtaq  S.,  Warner  M.,
Orthodox  and  unorthodox 
clavulanate  combinations 
against  extended-spectrum  β-
lactamase  producers,  Clinical 
Microbiology  and  Infection, 
2008; 14 (Suppl.1): 189-193.
20. Johnston  L.M.,  Jaykus  L.-A., 
Antimicrobial  Resistance  of 
Enterococcus Species  Isolated 
from  Produce,  Appl.  Environ. 
Microbiol.,  2004  May;  70(5): 
3133-3137.
21.  Figarolli B.M., Ossiprandi M.C., 
Ceppi  antibiotico-resistenti  di 
Enterococcus  Antibiotic-
resistant  strains  of 
Enterococcus, Ann. Fac. Medic. 
Vet.  di  Parma,  2006;  XXVI: 
219-234.
22.  Philippon  A.,  Cours  de 
Bactériologie  Générale  –
Antibiotiques  III:  Resistance 
bacterienne, Faculté  de 
Médecine  René  Descartes, 
Université  de  Paris  V,  2004, 
http://www.microbes-
edu.org/etudiant/antibio3.html
23.  Gerdes S., Scholle M., Campbell 
J.L.,  Balazsi  G.,  Ravasz  E., 
Daugherty  M.,  Somera  A.L., 
Kyrpides  N.,  Anderson  I., 
Gelfand  M.S.  et  al., 
Experimental determination and 
system-level  analysis  of 
essential  genes  in  E.  coli 
MG1655.  Journal  of 
Bacteriology,  2003;  185:  5673-
5684.
24. Wang  H.,  Benham  C.J., 
Promoter  prediction  and 
annotation of  microbial 
genomes  based  on  DNA 
sequence  and  structural 
responses to superhelical stress, 
BMC  Bioinformatics published 
by  BioMedCentral, May  2006; 
7(5): 248.
25.  Felmingham  D.,  White  A.R., 
Jacobs  M.R.  Appelbaum  P.C., 
Poupard  J.,  Miller  L.A., 
Grüneberg R.N., The Alexander 
Project:  the  benefits  from  a 
decade  of  surveillance,  Journal 
of Antimicrobial Chemotherapy, 
2005; 56 Suppl. S2: ii3-ii21.
26.  Elseviers  M.M.,  Ferech  M., 
Vander Stichele R.H., Goossens 
H.,  ESAC  project  group, 
Antibiotic  use  in  ambulatory 
care  in  Europe  (ESAC  data 
1997-2002):  trends,  regional 
differences  and  seasonal 
fluctuations, Journal of Medicine and Life  Vol. 2, No.2, April-June 2009 
122
© 2009, Carol Davila University Foundation
Pharmacoepidemiol  Drug  Saf, 
2007; 16(1): 115-23.
27. Muller  A.,  Coenen  S.,  Monnet 
D.L.,  Goossens  H.  şi  grupul 
proiectului  ESAC,  European 
Surveillance  of  Antimicrobial 
Consumption  (ESAC): 
outpatient  antibiotic  use  in 
Europe,  1998-2005, 
Eurosurveillance,  11  October 
2007; 12(10)
ttp://www.eurosurveillance.org/
ViewArticle.aspx?ArticleId=328
4
28.  Ferech  M.,  Coenen  S., 
Malhotra-Kumar S., Dvorakova 
K.,  Hendrickx  E.,  Suetens  C., 
Goossens  H.,  on  behalf  of  the 
ESAC Project Group, European 
Surveillance  of  Antimicrobial 
Consumption  (ESAC): 
outpatient  antibiotic  use  in 
Europe,  Journal  of 
Antimicrobial  Chemotherapy, 
2006; 58(2): 401-407.
29.  The  European  Antimicrobial 
Resistance  Surveillance  System 
(EARSS), EARSS  Annual 
Report  2007,  European 
Commission, 
http://www.rivm.nl/earss/
30.   Coculescu  B.-I.,  Flueraş  M., 
Mecanismul  mutaţiilor  genice,
Revista  de  Medicină  Militară,
2005; 4: 325-333.
31. Philippon  A.,  Cours  de 
Bactériologie  Générale  –
Genetique  bacterienne  I partie,
Faculté  de  Médecine  Cochin-
Port-Royal,  Université  de  Paris 
V, 2000.
32.  BioDeug,  Cours  de  biologie 
moléculaire  et  génétique  en 
ligne,  2006, 
http://www.biodeug.com/licence
.php
33.  Abad-Valle  P,  Fernández-
Abedul  MT,  Costa-García  A., 
DNA  single-base  mismatch 
study  with  an  electrochemical 
enzymatic  genosensor, 
Biosensors  and  Bioelectrons, 
2007 Mar 15; 22(8): 1642-50.
34.  Dinu V., Truţia E., Popa-Cristea 
E.,  Popescu  A.,  Biochimie 
Medicală  - mic  tratat.  Editura 
Medicală, Bucureşti, 1998.
35. Kapur V., Li L.L., Iordanescu S. 
et  al., Characterization  by 
automated  DNA  sequencing  of 
mutations  in  the  gene  (rpoB) 
encoding  the  RNA  polymerase 
beta  subunit  in  rifampin-
resistant  Mycobacterium 
tuberculosis strains  from  New 
York  City  and  Texas,  J  Clin 
Microbiol 1994; 32 (4):  1095-
1098.
36. Zhou Y.N.,  Jin D.J.,  The  rpoB 
mutants  destabilizing  initiation 
complexes  at  stringently 
controlled  promoters  behave 
like  “stringent”  RNA 
polymerases in Escherichia coli,
Proceedings  of  the  National 
Academy  of  Sciences  of  the 
USA,  March  17,  1998;  95(6): 
2908-2913.
37. Wichelhaus  T.A.,  Schäfer  V., 
Brade  V.,  Böddinghaus  B., 
Molecular  characterization  of 
rpoB  mutations  conferring 
cross-resistance  to  rifamycins 
on  methicillin-resistant 
Staphylococcus  aureus, 
Antimicrob  Agents  Chemother.
1999; 43 (11): 2813-2816.
38. Bobadilla-del-Valle  M.,  Ponce-
de-Leon A., Arenas-Huertero C. 
et al.,  rpoB  Gene  Mutations in 
Rifampin-Resistant 
Mycobacterium  tuberculosis
Identified by Polymerase Chain 
Reaction  Single-Stranded 
Conformational  Polymorphism, 
Emerging  Infectious  Diseases
Journal,  National  Center  for 
Infectious Diseases, Centers for 
Disease Control and Prevention, 
Atlanta,  nov-dec.  2001;  7(6): 
23-28.
39. Mokrousov  I.,  Otten  T., 
Vyshnevskiy B., Narvskaya O., 
Allele-Specific  rpoB PCR 
Assays  for  Detection  of 
Rifampin-Resistant 
Mycobacterium  tuberculosis in 
Sputum  Smears,  Antimicrobial 
Agents and Chemotherapy, July 
2003; 47 (7): 2231-2235.
40.  Wikipedia,  the  free 
encyclopedia 2008, 
http://en.wikipedia.org/wiki/200
8
41. Willmott  C.J.,  Maxwell  A.,  A 
single  point  mutation  in  the 
DNA  gyrase  A  protein  greatly 
reduces  binding  of 
fluoroquinolones to the gyrase-
DNA  complex.  Antimicrob 
Agents  Chemother.  1993 
January; 37(1): 126-127.
42. Heddle J., Maxwell A.,
Quinolone-Binding  Pocket  of 
DNA  Gyrase:  Role  of  GyrB, 
Antimicrobial  Agents  and 
Chemotherapy,  June  2002, 
46(6): 1805-1815.
43. Li-Fen Hu, Jia-Bin Li, Ying Ye, 
Xu  Li,  Mutations  in  the  GyrA 
Subunit of DNA Gyrase and the 
ParC Subunit of Topoisomerase 
IV  in  Clinical  Strains  of 
Fluoroquinolone-Resistant 
Shigella  in  Anhui,  China,  The 
Journal  of  Microbiology,  April 
2007; 45(2): 168-170.
44. Dutta  S.,  Kawamura  Y.,  Ezaki 
T.,  Nair  G.B.,  Iida  K-I.I., 
Yoshida  S-I.,  Alteration  in  the 
GyrA  subunit  of  DNA  gyrase 
and  the  ParC  subunit  of 
topoisomerase  IV  in 
quinoloneresistant  Shigella 
dysenteriae  serotype  1  clinical 
isolates  from  Kolkata,  India. 
Antimicrob. Agents Chemother.
2005, 49: 1660-1661.
45. Springer B., Kidan Y.G.,
Prammananan T., Ellrott K.,
Böttger E.C.,  Sander P.,
Mechanisms of streptomycin
resistance: selection of
mutations in the 16S rRNA gene
conferring resistance,
Antimicrobial Agents and
Chemotherapy. 2001; 45(10):
2877-2884.
46. Goodwin A., Kersulyte D.,
Sisson G., van Zanten S.J.O.V.,
Berg D.E., Hoffman P.S.,
Metronidazole resistance in
Helicobacter pylori is due to
null mutations in a gene (rdxA)
that encodes an oxygen-
insensitive NADPH
nitroreductase. Molecular
Microbiology 1998; 28: 383-
394.
47. Debets-Ossenkopp Y.J., Pot
R.G.J., van Westerloo D.J.,
Goddwin A., Vandenbroucke-
Grauls C.M.J.E., Berg D.E.,
Hoffman P.S., Kusters J.G.
Insertion of mini-IS605 and
deletion of adjacent sequences
in the nitroreductase (rdxA)
gene causes metronidazole
resistance in Helicobacter
pylori NCTC11637.
Antimicrobial Agents and
Chemotherapy. 1999; 43(11):
2657-2662.
48. Paul R., Postius S., Melchers K.,
Schäfer  K.P., Mutations of the
Helicobacter pylori genes rdxA
and pbp1 cause resistance
against metronidazole and
amoxicillin. Antimicrob  Agents Journal of Medicine and Life  Vol. 2, No.2, April-June 2009 
123
© 2009, Carol Davila University Foundation
Chemother. 2001 March; 45(3): 
962-965.
49. Negruţiu  L.,  Roşca  O., 
Mecanisme  moleculare  în 
rezistenţa  la  antibiotice, 
PulsMedia.ro,  Revista 
Infecţio.ro, nr. 3, XII 2005.
50. Bartlett  J.  G.,  Tratamentul 
bolilor infecţioase 2007: ghid de 
buzunar,  Editura  Medicală 
Amaltea, Bucureşti, 2007.
51. Romano  M.,  Iovene  M.R., 
Russo  M.I.,  Rocco  A.,  Salerno 
R.,  Cozzolino  D.,  Pilloni  A.P., 
Tufano M.A., Vaira D., 
Nardone G., Failure of first-line
eradication  treatment 
significantly  increases 
prevalence  of  antimicrobial-
resistant  Helicobacter  pylori
clinical  isolates,  Journal  of 
Clinical  Pathology, 2008; 
61(10): 1112-1115.
52. Vester  B.,  Douthwaite  S., 
Macrolide Resistance Conferred 
by  Base  Substitutions  in  23S 
rRNA,  Antimicrob  Agents 
Chemother. 2001; 45(1): 1-12.
53. Nakamura A., Furuta T., Shirai 
N., Sugimoto M., Kajimura M., 
Soya  Y.,  Hishida  A., 
Determination of mutations of
the  23S  rRNA  gene  of 
Helicobacter  pylori  by  allele 
specific  primer-polymerase 
chain  reaction  method,  Journal 
of  gastroenterology  and 
hepatology,  2007;  22(7):  1057-
1063.
54. Ladely S.R., Meinersmann R.J., 
Englen  M.D.,  Fedorka-Cray 
P.J.,  Mark  A.  Harrison  M.A., 
23S  rRNA  Gene  Mutations 
Contributing  to  Macrolide 
Resistance  in  Campylobacter 
jejuni and  Campylobacter  coli, 
Foodborne  Pathogens  and 
Disease, 2009; 6(1): 19-24.